MaxCyte Company Insiders

MaxCyte Management Team Effectiveness

The company has return on total asset (ROA) of (0.1125) % which means that it has lost $0.1125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.16) %, meaning that it created substantial loss on money invested by shareholders. MaxCyte's management efficiency ratios could be used to measure how well MaxCyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2024. Return On Capital Employed is likely to gain to -0.18 in 2024. At this time, MaxCyte's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 19.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 9.7 M in 2024. Common Stock Shares Outstanding is likely to drop to about 66.8 M in 2024. Net Loss is likely to drop to about (22.3 M) in 2024

MaxCyte Workforce Comparison

MaxCyte Profit Margins

The company has Profit Margin (PM) of (0.78) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.72.

MaxCyte Insider Trading History

MaxCyte Notable Stakeholders

The success or failure of an entity such as MaxCyte often depends on how effective the management is. MaxCyte management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MaxCyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MaxCyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in MaxCyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MaxCyte. Check MaxCyte's Beneish M Score to see the likelihood of MaxCyte's management manipulating its earnings.

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.